- Home
- CITE vs SCLX Comparison
CITE vs SCLX Comparison
Compare CITE & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CITE
- SCLX
- Stock Information
- Founded
- CITE 2021
- SCLX 2011
- Country
- CITE United States
- SCLX United States
- Employees
- CITE N/A
- SCLX N/A
- Industry
- CITE
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- CITE
- SCLX Health Care
- Exchange
- CITE NYSE
- SCLX Nasdaq
- Market Cap
- CITE 93.6M
- SCLX 81.7M
- IPO Year
- CITE 2022
- SCLX N/A
- Fundamental
- Price
- CITE $11.68
- SCLX $0.41
- Analyst Decision
- CITE
- SCLX Strong Buy
- Analyst Count
- CITE 0
- SCLX 3
- Target Price
- CITE N/A
- SCLX $11.33
- AVG Volume (30 Days)
- CITE 35.0K
- SCLX 184.3K
- Earning Date
- CITE 01-01-0001
- SCLX 01-07-2025
- Dividend Yield
- CITE N/A
- SCLX N/A
- EPS Growth
- CITE N/A
- SCLX N/A
- EPS
- CITE N/A
- SCLX N/A
- Revenue
- CITE N/A
- SCLX $50,833,000.00
- Revenue This Year
- CITE N/A
- SCLX $32.77
- Revenue Next Year
- CITE N/A
- SCLX $50.71
- P/E Ratio
- CITE N/A
- SCLX N/A
- Revenue Growth
- CITE N/A
- SCLX 9.41
- 52 Week Low
- CITE $10.89
- SCLX $0.39
- 52 Week High
- CITE $12.25
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- CITE 60.80
- SCLX 29.05
- Support Level
- CITE $11.61
- SCLX $0.43
- Resistance Level
- CITE $11.75
- SCLX $0.51
- Average True Range (ATR)
- CITE 0.03
- SCLX 0.06
- MACD
- CITE -0.01
- SCLX -0.01
- Stochastic Oscillator
- CITE 60.00
- SCLX 6.79
About CITE CARTICA ACQUISITION CORP
Cartica Acquisition Corp is a blank check company.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.